US pandemic preparedness got a boost with the Center for Biologics Evaluation and Research’s approval of Seqirus’ Audenz, a pandemic influenza A (H5N1) vaccine destined for the national stockpile, while Trevena Inc. tried to chip away at another issue of national significance – the opioid crisis – with the resubmission of its novel IV opioid for acute pain, oliceridine.
Competition for Genentech Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?